## Proto-oncogenes and Activation Frequency **Key Point:** RAS proto-oncogene is activated in approximately 30% of all human cancers, making it the single most frequently mutated oncogene across all malignancies. ### RAS Gene Characteristics **High-Yield:** RAS (HRAS, KRAS, NRAS) encodes a small GTPase protein involved in signal transduction. Mutations typically occur at codons 12, 13, or 61, resulting in constitutive activation and loss of GTPase activity. ### Tissue-Specific Activation Patterns | Cancer Type | RAS Mutation Frequency | Common Isoform | | --- | --- | --- | | Pancreatic adenocarcinoma | 90% | KRAS | | Colorectal cancer | 40–50% | KRAS | | Lung cancer (non-small cell) | 30% | KRAS | | Melanoma | 25–30% | NRAS | | Acute myeloid leukemia | 20–30% | NRAS, KRAS | **Clinical Pearl:** KRAS mutations in pancreatic cancer are nearly universal and represent an early event in carcinogenesis, making them a potential biomarker for early detection. ### Mechanism of Oncogenic Transformation 1. Wild-type RAS cycles between inactive (GDP-bound) and active (GTP-bound) states 2. Mutant RAS remains locked in GTP-bound active state 3. Continuous downstream signaling through RAF-MEK-ERK pathway 4. Uncontrolled cell proliferation independent of growth factor signals **Mnemonic:** **RAS = Rapid Abnormal Signaling** — constitutively active due to loss of intrinsic GTPase activity. ### Why RAS is Most Common - Single point mutations are sufficient for activation (unlike multi-hit tumor suppressors) - Affects multiple signaling pathways simultaneously (MAPK, PI3K) - Present in diverse cancer types and tissues - Early event in multi-step carcinogenesis [cite:Robbins 10e Ch 7]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.